“I am extremely proud of the clinical progress our team has made over this past quarter. The initiation of our Phase 1 clinical trial and patient enrollment and dosing are important milestones in our clinical program,” commented J.D. Finley, Chief Executive Officer of Palisade. “We continue to believe in the potential of PALI-2108 to provide a much-needed solution for UC patients still experiencing significant medical need.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio announces first subject dosed in Phase 1 study of PALI-2108
- Palisade Bio announces data from two ex vivo studies of PALI-2108
- Palisade Bio files to sell common stock, warrants, no amount given
- Palisade Bio received No Objection Letter from Health Canada for Phase 1 study
- Palisade Bio CEO Finley’s Revised Employment and Compensation Deal
Questions or Comments about the article? Write to editor@tipranks.com